Lab Results
Insulin: Why Fasting Insulin Is More Useful Than Glucose for Metabolic Health
Your fasting glucose can look perfectly normal while your insulin is silently working overtime — a warning sign that standard metabolic panels completely miss. Elevated fasting insulin is one of the earliest detectable markers of insulin resistance, often appearing a decade before blood sugar crosses a diagnostic threshold. Understanding what your fasting insulin number actually means could be the most important metabolic insight your lab work has never shown you.
Insulin: Why Fasting Insulin Is More Useful Than Glucose for Metabolic Health
Most people who get a standard metabolic panel walk away knowing their fasting glucose number. If it's under 100 mg/dL, they're told everything looks fine. But that reassurance can be dangerously incomplete. Fasting glucose is a lagging indicator — it rises only after the pancreas has been compensating for insulin resistance for years, sometimes decades. Fasting insulin, by contrast, captures that compensatory effort in real time. It is arguably the single most underutilized marker in routine metabolic screening.
This article breaks down what the fasting insulin blood test actually measures, why it outperforms fasting glucose as an early warning signal, how to interpret your results using the HOMA-IR calculation, and what optimal levels look like based on current clinical evidence.
---
Why Fasting Glucose Alone Misses the Early Warning
When cells become less sensitive to insulin, the pancreas compensates by secreting more of it. For a period that can span many years, this compensatory hyperinsulinemia successfully keeps blood glucose in a normal range. During that window, a fasting glucose test will return a number between 70 and 99 mg/dL — technically "normal" — while the underlying metabolic dysfunction quietly progresses.
A landmark analysis of the NHANES dataset found that an estimated 88% of American adults have at least one marker of poor metabolic health, yet many fall within standard glucose reference ranges (Araújo et al., Metabolic Syndrome and Related Disorders, 2019; PMID: 30484738). The study defined metabolic health across five parameters — blood glucose, triglycerides, HDL cholesterol, blood pressure, and waist circumference — and its findings underscore how relying on glucose alone paints an incomplete picture.
Fasting insulin fills that gap. Because insulin must rise to maintain glucose homeostasis in the face of cellular resistance, elevated fasting insulin is detectable years — sometimes a full decade — before fasting glucose climbs into the prediabetic range (Tabák et al., The Lancet, 2009; PMID: 19515410). Ordering a fasting insulin alongside a standard glucose panel is a simple, inexpensive upgrade that can shift your entire metabolic risk assessment.
---
Insulin Resistance Lab Test: What You're Actually Measuring
Insulin resistance is not a single test but a physiological state — and it has no perfect laboratory surrogate. The gold standard for measuring it is the euglycemic-hyperinsulinemic clamp, a research procedure that directly quantifies how efficiently tissues take up glucose under controlled insulin infusion. It is impractical for routine clinical use.
In practice, the most accessible insulin resistance lab test toolkit includes:
| Test | What It Measures | Limitations |
|---|---|---|
| Fasting glucose | Blood sugar after overnight fast | Rises late in disease progression |
| HbA1c | Average glucose over ~90 days | Misses short-term fluctuations; affected by RBC lifespan |
| Fasting insulin | Baseline insulin secretion | No universal reference range across labs |
| HOMA-IR | Calculated insulin × glucose ratio | Validated proxy for clamp; still an estimate |
| Triglyceride/HDL ratio | Surrogate for insulin resistance | Indirect; influenced by diet |
| C-peptide | Endogenous insulin production | Useful to distinguish insulin types |
For most people outside a research setting, the combination of fasting insulin plus fasting glucose — used to calculate HOMA-IR — provides the most actionable signal. If you are tracking your metabolic biomarkers over time, adding fasting insulin to each panel creates a meaningful longitudinal picture that glucose alone cannot.
---
HOMA-IR Calculation: What the Formula Actually Tells You
HOMA-IR stands for Homeostatic Model Assessment of Insulin Resistance. It was developed by Matthews and colleagues and published in Diabetologia in 1985 — a foundational citation still referenced in clinical practice today (Matthews et al., Diabetologia, 1985; PMID: 3899825).
The formula is straightforward:
HOMA-IR = (Fasting Insulin [µIU/mL] × Fasting Glucose [mg/dL]) ÷ 405
(If glucose is reported in mmol/L, divide by 22.5 instead of 405.)
Example: A fasting insulin of 10 µIU/mL paired with a fasting glucose of 90 mg/dL yields a HOMA-IR of (10 × 90) ÷ 405 = 2.2.
HOMA-IR Reference Ranges
| HOMA-IR Score | Interpretation |
|---|---|
| < 1.0 | Optimal insulin sensitivity |
| 1.0 – 1.9 | Acceptable; monitor trends |
| 2.0 – 2.9 | Early insulin resistance; lifestyle intervention warranted |
| ≥ 3.0 | Significant insulin resistance |
| ≥ 5.0 | Severe insulin resistance; clinical evaluation recommended |
These thresholds are broadly consistent with cut-points used in large epidemiological studies. A prospective cohort study of over 1,000 non-diabetic adults found that HOMA-IR values above 2.5 were independently associated with significantly higher risk of developing type 2 diabetes over a 7.5-year follow-up (Hanley et al., Diabetes Care, 2002; PMID: 11815503).
One important nuance: reference ranges for HOMA-IR can shift slightly depending on ethnicity, age, and BMI-adjusted populations. South Asian individuals, for instance, tend to show metabolic complications at lower HOMA-IR thresholds than individuals of European descent — a clinically relevant point when interpreting borderline results (Misra et al., Obesity Reviews, 2009; PMID: 19563464).
---
Optimal Fasting Insulin Level: What the Research Actually Supports
Here is where clinical practice and optimal health diverge. Many commercial laboratory reference ranges list fasting insulin as "normal" anywhere up to 24 or even 29 µIU/mL. These ranges are derived from population distributions — they describe what is statistically common, not what is metabolically healthy.
Research from functional and preventive medicine practitioners converges on a much tighter optimal fasting insulin level. Based on data from multiple large epidemiological studies:
- Optimal: 2–6 µIU/mL
- Acceptable: 6–10 µIU/mL
- Borderline elevated: 10–15 µIU/mL
- Elevated (insulin resistance likely): > 15 µIU/mL
A cross-sectional analysis using NHANES data found that fasting insulin levels above 7 µIU/mL in non-diabetic adults were associated with a significantly higher prevalence of metabolic syndrome components, independent of fasting glucose status (Levy et al., Diabetes Care, 1998; PMID: 9571333).
For context: a person with a fasting insulin of 18 µIU/mL and a fasting glucose of 88 mg/dL would have a HOMA-IR of approximately 3.9 — well into the insulin-resistant range — yet their standard metabolic panel might generate no clinical flags whatsoever.
This gap between "normal by lab reference" and "optimal for health" is precisely why understanding how to interpret your blood work beyond standard reference ranges is so valuable for proactive health management.
---
Hyperinsulinemia: The Downstream Consequences That Go Beyond Blood Sugar
Hyperinsulinemia — chronically elevated circulating insulin — is not merely a side effect of insulin resistance. Growing evidence suggests it is independently pathological, driving a cascade of downstream effects that extend well beyond glucose metabolism.
Cardiovascular Risk
Insulin is a growth-promoting hormone. Chronically elevated levels stimulate smooth muscle cell proliferation in arterial walls and promote dyslipidemia — particularly elevated triglycerides and reduced HDL. A meta-analysis of prospective cohort studies found that hyperinsulinemia was an independent predictor of cardiovascular events, even after adjusting for traditional risk factors including LDL cholesterol and blood pressure (Ruige et al., Arteriosclerosis, Thrombosis, and Vascular Biology, 1998; PMID: 9514397).
Hormonal Disruption
In women, elevated insulin stimulates ovarian androgen production and suppresses sex hormone-binding globulin (SHBG), contributing to the hormonal pattern seen in polycystic ovary syndrome (PCOS). Studies estimate that 50–80% of women with PCOS have measurable insulin resistance, and lowering insulin levels through dietary or pharmacological intervention improves both hormonal and reproductive outcomes (Teede et al., Nature Reviews Endocrinology, 2022; PMID: 35654827).
Cognitive Function
The brain is an insulin-sensitive organ. Chronic hyperinsulinemia and the resulting receptor downregulation have been linked to impaired neuronal insulin signaling — a mechanism some researchers describe as a contributor to neurodegenerative risk. Epidemiological studies have found associations between higher fasting insulin and accelerated cognitive decline in non-diabetic adults (Craft et al., Archives of Neurology, 2012; PMID: 22232206).
Cancer Biology
Insulin is mitogenic. Elevated circulating insulin increases IGF-1 bioavailability by reducing IGFBP levels, creating a pro-growth environment. The American Institute for Cancer Research and World Cancer Research Fund have both identified insulin resistance and hyperinsulinemia as part of the mechanistic pathway linking excess body fat to increased cancer risk (WCRF/AICR Continuous Update Project, 2018).
Understanding the full scope of hyperinsulinemia's downstream effects makes a compelling case for testing fasting insulin proactively — not just when blood sugar becomes a concern.
---
What Moves Fasting Insulin: Diet, Lifestyle, and Targeted Nutrition
Fasting insulin is meaningfully modifiable. The interventions with the strongest evidence base include:
- Carbohydrate quality and quantity — Replacing refined carbohydrates and added sugars with fiber-rich whole foods reduces postprandial insulin demand and lowers fasting insulin over time. A systematic review of 27 randomized controlled trials found low-glycemic index diets significantly reduced fasting insulin compared to higher-GI comparators (Schwingshackl et al., Nutrients, 2019; PMID: 30781471).
- Resistance training — Skeletal muscle is the primary site of insulin-mediated glucose uptake. Building and maintaining muscle mass increases metabolic glucose disposal capacity and improves insulin sensitivity. A meta-analysis of 21 trials found resistance training significantly reduced HOMA-IR in adults with insulin resistance (Bacchi et al., PLOS ONE, 2013; PMID: 23894519).
- Time-restricted eating — Compressing the eating window to 8–10 hours has been shown to reduce fasting insulin independently of caloric restriction in several pilot trials, though larger long-term studies are still ongoing (Sutton et al., Cell Metabolism, 2018; PMID: 29754952).
- Sleep quality — Even one week of sleep restriction (5.5 hours/night) has been shown to reduce insulin sensitivity by approximately 25% in healthy adults (Nedeltcheva et al., Annals of Internal Medicine, 2010; PMID: 20516264).
- Targeted micronutrient support — Several clinically studied nutrients play specific roles in insulin signaling and glucose metabolism, which brings us to how precision supplementation fits into this picture.
---
What This Means for Your Formula
When Ones analyzes your lab results — including fasting insulin and glucose — it maps your data against clinical thresholds, not just population reference ranges. If your HOMA-IR, fasting insulin trend, or triglyceride/HDL ratio suggests early insulin resistance, your personalized formula can incorporate ingredients with direct mechanistic and clinical evidence in this area.
Berberine has been studied extensively for its role in activating AMPK, the cellular energy-sensing enzyme that plays a central role in glucose uptake and insulin signaling. A meta-analysis of 14 randomized trials found berberine significantly reduced fasting glucose, fasting insulin, and HOMA-IR compared to placebo (Liang et al., Metabolism, 2019; PMID: 31060773). Ones sources berberine in its clinically relevant range consistent with doses used in these trials.
Magnesium Glycinate is a foundational inclusion for anyone with elevated insulin markers. Magnesium acts as a cofactor for over 300 enzymatic reactions, including the insulin receptor tyrosine kinase pathway. A meta-analysis of prospective studies found that higher dietary magnesium intake was inversely associated with type 2 diabetes risk, with each 100 mg/day increment associated with a 15% risk reduction (Dong et al., Diabetes Care, 2011; PMID: 21209269). Ones uses the glycinate chelate form, which offers superior gastrointestinal tolerance and bioavailability compared to oxide forms. For more on how this mineral works across body systems, the evidence behind magnesium glycinate for metabolic and sleep health offers additional clinical context.
Chromium Picolinate has a specific evidence base in insulin sensitivity. A systematic review found supplemental chromium modestly but significantly reduced fasting insulin and HOMA-IR in individuals with glucose dysregulation, with effect sizes correlating with baseline impairment (Tian et al., Nutrition & Metabolism, 2013; PMID: 23394705). It is included in Ones formulas where lab data and health goals indicate a glucose regulation priority.
Alpha-Lipoic Acid (ALA) acts as both a direct insulin sensitizer and an antioxidant that reduces oxidative stress — one of the amplifying mechanisms in insulin resistance pathology. Clinical trials using 600mg/day of ALA have demonstrated significant reductions in fasting insulin and improvements in insulin-stimulated glucose disposal (Konrad et al., Diabetes Care, 1999; PMID: 10426250).
Beyond individual ingredients, Ones formulas are calibrated to your capsule budget — whether a 6, 9, or 12-capsule plan — so these metabolic support ingredients are prioritized based on the actual signal in your labs, not a generic protocol. If you are also managing thyroid function alongside metabolic health, Ones can address both systems within the same personalized formula, since thyroid and insulin signaling are deeply interconnected.
For individuals wanting the deepest level of metabolic tracking, platforms like Function Health offer comprehensive lab panels that include fasting insulin — and pairing those insights with an AI-driven supplement protocol like Ones creates a genuinely personalized metabolic strategy.
---
Key Takeaways
- Fasting glucose is a lagging indicator. Fasting insulin rises years before blood sugar crosses diagnostic thresholds, making it a far more sensitive early-warning marker for insulin resistance.
- The HOMA-IR calculation (fasting insulin × fasting glucose ÷ 405) is a validated, accessible proxy for insulin resistance. A score below 1.0 reflects optimal sensitivity; above 2.5–3.0 warrants intervention.
- Lab reference ranges overstate "normal." Many labs flag fasting insulin as acceptable up to 24 µIU/mL. Research supports an optimal range of 2–6 µIU/mL for metabolic health.
- Hyperinsulinemia has systemic consequences beyond blood sugar — including cardiovascular risk, hormonal disruption in women, accelerated cognitive decline, and pro-growth signaling relevant to cancer biology.
- Fasting insulin is modifiable through carbohydrate quality, resistance training, sleep optimization, time-restricted eating, and evidence-based micronutrient support including berberine, magnesium glycinate, chromium, and alpha-lipoic acid.
- Ones uses your actual lab data — including fasting insulin and HOMA-IR — to build a personalized formula targeting the specific metabolic pathways where your numbers show the greatest need, dosed to clinically validated ranges.